chronic myelomonocytic leukemia
Showing NaN - NaN of 38
Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2023
Myelofibrosis, Chronic Myelomonocytic Leukemia Trial in Canada, United States (SL-401)
Active, not recruiting
- Myelofibrosis
- Chronic Myelomonocytic Leukemia
-
Duarte, California
- +9 more
Jan 24, 2023
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in Worldwide (Decitabine, PDR001, MBG453)
Active, not recruiting
- Leukemia
- +7 more
- Decitabine
- +3 more
-
Boston, Massachusetts
- +10 more
Jan 19, 2023
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston
Recruiting
- Chronic Myelomonocytic Leukemia
- +5 more
- Canakinumab
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS Trial in Canada, United States (ASTX727)
Enrolling by invitation
- Acute Myeloid Leukemia
- +2 more
-
Fountain Valley, California
- +28 more
Nov 18, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Houston (DSP107, Azacitidine, Venetoclax)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- DSP107
- +2 more
-
Houston, TexasThe University of Texas MD Anderson Cancer Center, Department of
Nov 13, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia
Completed
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +14 more
- Aldesleukin
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +5 more
- CFI-400945
- +2 more
-
Duarte, California
- +7 more
Jul 20, 2022
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)
Recruiting
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Decitabine and Cedazuridine
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Tumor Trial in Houston (Azacitidine, Quizartinib)
Recruiting
- Chronic Myelomonocytic Leukemia
- +5 more
-
Houston, TexasM D Anderson Cancer Center
May 23, 2022
Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,
Active, not recruiting
- Acute Myeloid Leukemia
- +6 more
- Azacitidine
- +2 more
-
Baltimore, Maryland
- +2 more
Feb 25, 2022
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston
Recruiting
- Chronic Myelomonocytic Leukemia
- +3 more
- Decitabine
- Tagraxofusp-erzs
-
Houston, TexasM D Anderson Cancer Center
Mar 4, 2022
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of
Active, not recruiting
- Acute Myeloid Leukemia With Multilineage Dysplasia
- +6 more
- Azacitidine
- Glutaminase Inhibitor CB-839
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Tumor Trial in United States (APR-246, Azacitidine)
Completed
- Myelodysplastic Syndrome
- +3 more
-
Tampa, Florida
- +5 more
Jan 14, 2022
Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera Trial in Houston (Imatinib Mesylate (Gleevec))
Completed
- Chronic Myelomonocytic Leukemia
- +4 more
- Imatinib Mesylate (Gleevec)
-
Houston, TexasUT MD Anderson Cancer Center
Dec 7, 2021
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in France, United States (oral
Completed
- Myelodysplastic Syndrome
- +2 more
- oral rigosertib
- Azacitidine
-
Gilbert, Arizona
- +12 more
Jun 15, 2021
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial in Philadelphia, Houston (Decitabine,
Completed
- Acute Myeloid Leukemia
- +2 more
- Decitabine
- +2 more
-
Philadelphia, Pennsylvania
- +1 more
May 18, 2021
MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Worldwide (Panobinostat (LBH589), 5-Azacytidine)
Completed
- Myelodysplastic Syndromes
- +2 more
- Panobinostat (LBH589)
- 5-Azacytidine
-
Augusta, Georgia
- +37 more
Jul 20, 2020
MDS, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia Trial in Worldwide (rigosertib sodium)
Completed
- Myelodysplastic Syndromes
- +3 more
- rigosertib sodium
-
Stanford, California
- +34 more
Jun 29, 2020
MDS, MDS, RAEB Trial in Worldwide (ON 01910.Na)
Completed
- Myelodysplastic Syndromes
- +3 more
- ON 01910.Na
-
Scottsdale, Arizona
- +86 more
Jun 29, 2020
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22);
Completed
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +10 more
- Erlotinib Hydrochloride
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Dec 18, 2019